Ocugen

Request removal

Ocugen Inc. (NASDAQ: OCGN) is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – "one to many" and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.

URLs

website: https://www.ocugen.com
facebook: https://facebook.com/HistogenicsCorp/
twitter: https://twitter.com/Ocugen
linkedin: http://www.linkedin.com/company/ocugen

Get valid emails for people working at Ocugen and 200M other companies

20 free emails each month. No credit card required.

500M

Business Profiles

20M

Company Profiles

200M

Email addresses

98%+

Email Delivery

Ocugen's headquarter address

Line 1: 263 great valley parkway, malvern, pennsylvania, united states, 19355

Line 2: 263 Great Valley Parkway

Ocugen's industries

Biotechnology Research

Ocugen's technology

Akamai RUM Apache Google Cloud Hosting Google Font API Google Tag Manager Mobile Friendly New Relic Outlook WordPress.org reCAPTCHA

People working at Ocugen

Courtney Lonchena

Director Clinical Operations

Michael Shine

Senior Vice President, Commercial